​

Bicara Therapeutics Ownership | Who Owns Bicara Therapeutics?


OverviewForecastFinancialsChartTranscripts

Bicara Therapeutics Ownership Summary


Bicara Therapeutics is owned by 101.96% institutional investors, 10.04% insiders. Ra capital management is the largest institutional shareholder, holding 11.95% of BCAX shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 3.27% of its assets in Bicara Therapeutics shares.

BCAX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBicara Therapeutics101.96%10.04%-11.99%
SectorHealthcare Stocks 129.40%12.08%-41.48%
IndustryBiotech Stocks 181.71%11.69%-93.40%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management7.26M11.95%$215.43M
T. rowe price investment management6.34M10.44%$188.19M
Vestal point capital, lp5.25M8.65%$155.87M
Siren5.50M8.10%$102.41M
Deep track capital, lp4.10M6.75%$121.73M
Janus henderson group3.33M6.08%$66.11M
Blackrock funding, inc. /de3.95M5.81%$73.43M
Tpg gp a3.01M4.96%$89.38M
Red tree management2.92M4.30%$54.35M
Vanguard group2.19M4.01%$36.79M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Red tree management2.92M46.57%$54.35M
Omega fund management1.82M29.14%$54.10M
Acorn capital advisors643.38K5.21%$19.10M
Vestal point capital, lp5.25M3.64%$155.87M
Aisling capital management lp548.92K3.41%$10.22M
Jones hill capital lp1.06M3.36%$19.81M
Superstring capital management lp175.90K2.74%$2.78M
Siren5.50M2.42%$102.41M
Palo alto investors lp550.41K2.26%$16.34M
Ra capital management7.26M1.87%$215.43M

Top Buyers

HolderShares% AssetsChange
Franklin resources2.67M0.01%713.25K
Janus henderson group3.33M0.03%680.63K
Price t rowe associates inc /md/1.90M0.01%528.05K
Ameriprise financial288.75K0.00%272.93K
Schonfeld strategic advisors504.08K0.05%241.33K

Top Sellers

HolderShares% AssetsChange
Royalty pharma sub-manager---2.39M
Braidwell lp---2.16M
Deerfield management company, l.p. (series c)---1.80M
Citadel advisors211.14K0.00%-1.45M
Wellington management group llp---1.39M

New Positions

HolderShares% AssetsChangeValue
Qube research210.93K0.00%210.93K$3.93M
Cantor fitzgerald, l. p.100.00K0.01%100.00K$1.58M
Quadrature capital65.98K0.01%65.98K$1.23M
Exoduspoint capital management, lp53.88K0.01%53.88K$850.80K
Norges bank42.89K0.00%42.89K$721.82K

Sold Out

HolderChange
Aster capital management (difc)-1.00
Sbi securities-1.00
Clearstead advisors-5.00
Stone house investment management-11.00
National bank of canada /fi/-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2026177-3.80%69,255,507-4.55%1010.71%102-10.53%39-
Jun 30, 202618016.88%72,477,8081.71%1190.70%11022.22%39-2.50%
Mar 31, 202678-45.83%15,246,758-73.87%270.24%48-46.67%17-51.43%
Dec 31, 202592-19.30%27,836,301-44.55%510.60%57-12.31%23-14.81%
Sep 30, 20251115.71%49,553,927-3.15%901.03%64-18.99%2662.50%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price US Small-Cap Core Equity2.15M3.27%-33.46K
Vanguard Total Stock Mkt Idx Inv1.68M2.55%305.30K
Vanguard Morn Total Stk Mkt Idx Investor1.68M2.55%305.30K
Vanguard MStar Total Stk Mkt Idx Invest1.68M2.53%-
State Street® SPDR® S&P® Biotech ETF1.17M1.77%30.59K
iShares Russell 2000 ETF1.11M1.68%-
T. Rowe Price U.S. SC Core Eq Tr-D1.00M1.53%-29.85K
T. Rowe Price Small-Cap Stock973.67K1.47%-630.88K
Fidelity Select Biotechnology902.00K1.36%-42.90K
Franklin Biotechnology Discv A(acc)USD877.99K1.33%-

Recent Insider Transactions


DateNameRoleActivityValue
Sep 08, 2026Cohlhepp Ryan President, COO & Interim CEOSell$80.66K
Sep 08, 2026Cohlhepp Ryan President, COO & Interim CEOSell$320.05K
Aug 10, 2026Hyep Ivan Chief Financial OfficerSell$349.59K
Aug 10, 2026Mazumdar Claire Chief Executive OfficerSell$279.75K
Aug 10, 2026Cohlhepp Ryan President and COOSell$524.53K

Insider Transactions Trends


DateBuySell
2026 Q3-14
2026 Q2-10
2026 Q1221
2025 Q4-23
2025 Q3-2

BCAX Ownership FAQ


Who Owns Bicara Therapeutics?

Bicara Therapeutics shareholders are primarily institutional investors at 101.96%, followed by 10.04% insiders and -12.00% retail investors. The average institutional ownership in Bicara Therapeutics's industry, Biotech Stocks , is 181.71%, which Bicara Therapeutics falls below.

Who owns the most shares of Bicara Therapeutics?

Bicara Therapeutics’s largest shareholders are Ra capital management (7.26M shares, 11.95%), T. rowe price investment management (6.34M shares, 10.44%), and Vestal point capital, lp (5.25M shares, 8.65%). Together, they hold 31.04% of Bicara Therapeutics’s total shares outstanding.

Does Blackrock own Bicara Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Bicara Therapeutics.

Who is Bicara Therapeutics’s biggest shareholder by percentage of total assets invested?

Red tree management is Bicara Therapeutics’s biggest shareholder by percentage of total assets invested, with 46.57% of its assets in 2.92M Bicara Therapeutics shares, valued at 54.35M$.

Who is the top mutual fund holder of Bicara Therapeutics shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Bicara Therapeutics shares, with 3.27% of its total shares outstanding invested in 2.15M Bicara Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools